Company news

Seastar Medical Holding Corporation (NASDAQ:ICU) news

Seastar Medical Holding Corporation news releases on 6ix. Latest, May 14, 2025: SeaStar Medical Reports First Quarter 2025 Financial Results and Provides…

Seastar Medical Holding Corporation (NASDAQ:ICU) news

Press releases — page 2

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

SeaStar Medical Announces $6 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Adds Fifth Hospital Customer for QUELIMMUNE

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner

SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company

SeaStar Medical Announces 25-for-1 Reverse Stock Split

SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

SeaStar Medical Appoints David A. Green as Chief Financial Officer

SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications

SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

FDA Grants Breakthrough Device Designation to SeaStar Medical’s Selective Cytopheretic Device for Cardiorenal Syndrome

SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update